title: Interferon-alpha 2b is not effective in the treatment of refractory immune thrombocytopenic purpura.
abstract: About 25-30% of patients with immune thrombocytopenic purpura (ITP) are refractory to corticosteroids, splenectomy and other treatments. It has been suggested that interferon-alpha 2b (IFN-alpha 2b) may be useful in the treatment of chronic refractory ITP patients. We treated 9 chronic refractory ITP patients with IFN-alpha 2b: the results were poor.
authors.forename: N
authors.initials: N
authors.lastname: Vianelli
authors.forename: P L
authors.initials: PL
authors.lastname: Tazzari
authors.forename: S
authors.initials: S
authors.lastname: Baravelli
authors.forename: F
authors.initials: F
authors.lastname: Ricci
authors.forename: L
authors.initials: L
authors.lastname: Valdrè
authors.forename: S
authors.initials: S
authors.lastname: Tura
mesh_terms: D000328:Adult; D000368:Aged; D001327:Autoimmune Diseases / Q000628:therapy*; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000628:therapy*; D011994:Recombinant Proteins; D016879:Salvage Therapy; D017211:Treatment Failure
chemical_list: D007155:Immunologic Factors; D007166:Immunosuppressive Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins